The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
Long-Term Results : With continued use, individuals can sustain weight loss
Easy process and the doctor was super friendly
However, patients should be cautioned that exercise capacity may be temporarily reduced during the initial treatment period, and expectations should be adjusted accordingly
Therefore, additional studies are required to assess the impact of cardiovascular, renal and hepatic outcomes, which could be compared in a future NMA
Sleep quality and cortisol rhythms directly impact weight loss on any therapy